Literature DB >> 23905713

Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis.

Russell E Lewis1, Sarah P Georgiadou, Fotis Sampsonas, George Chamilos, Dimitrios P Kontoyiannis.   

Abstract

Pulmonary mucormycosis (PM) is a life-threatening opportunistic mycosis with a variable clinical evolution and few prognostic markers for outcome assessment. Several clinical risk factors for poor outcome present at the diagnosis of PM were analyzed in 75 consecutive hematology patients from 2000-2012. Significant variables (P < 0.1) were entered into a multivariate Cox-proportional hazard regression model adjusting for baseline APACHE II to identify independent risk factors for mortality within 28 days. Twenty-eight of 75 patients died within 4-week follow up. A lymphocyte count < 100/mm³ at the time of diagnosis (adjusted hazard ratio 4.0, 1.7-9.4, P = 0.01) and high level of lactate dehydrogenase (AHR 3.7, 1.3-10.2, P = 0.015) were independent predictors along with APACHE II score for 28-day mortality. A weighted risk score based on these 3 baseline variables accurately identified non-surviving patients at 28 days (area under the receiver-operator curve of 0.87, 0.77-0.93, P < 0.001). A risk score > 22 was associated with 8-fold high rates of mortality (P < 0.0001) within 28 days of diagnosis and median survival of 7 days versus ≥28 days in patients with risk scores ≤22. We found that APACHE II score, severe lymphocytopenia and high LDH levels at the time of PM diagnosis were independent markers for rapid disease progression and death.
© 2013 Blackwell Verlag GmbH.

Entities:  

Keywords:  Mucormycosis; lymphocytopenia; risk index score

Mesh:

Year:  2013        PMID: 23905713      PMCID: PMC3867535          DOI: 10.1111/myc.12101

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  28 in total

Review 1.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

2.  Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).

Authors:  L Pagano; P Ricci; A Tonso; A Nosari; L Cudillo; M Montillo; A Cenacchi; L Pacilli; F Fabbiano; A Del Favero
Journal:  Br J Haematol       Date:  1997-11       Impact factor: 6.998

Review 3.  Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

Review 4.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

5.  Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation.

Authors:  P Ribaud; C Chastang; J P Latgé; L Baffroy-Lafitte; N Parquet; A Devergie; H Espérou; F Sélimi; V Rocha; H Espérou; F Sélimi; V Rocha; F Derouin; G Socié; E Gluckman
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

Review 6.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

7.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

8.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079

9.  Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers.

Authors:  Catherine Cordonnier; Patricia Ribaud; Raoul Herbrecht; Noël Milpied; Dominique Valteau-Couanet; Caroline Morgan; Amath Wade
Journal:  Clin Infect Dis       Date:  2006-02-22       Impact factor: 9.079

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  6 in total

1.  Development of new strategies for early diagnosis of mucormycosis from bench to bedside.

Authors:  Thomas J Walsh; Anna Skiada; Oliver A Cornely; Emmanuel Roilides; Ashraf Ibrahim; Theoklis Zaoutis; Andreas Groll; Olivier Lortholary; Dimitrios P Kontoyiannis; George Petrikkos
Journal:  Mycoses       Date:  2014-12       Impact factor: 4.377

2.  Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis.

Authors:  Hayoung Choi; Hyun Lee; Kyeongman Jeon; Gee Young Suh; Sumin Shin; Hong Kwan Kim; Kyunga Kim; Daecheon Jeong; Hojoong Kim
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

Review 3.  Mucorales Species and Macrophages.

Authors:  Francisco E Nicolás; Laura Murcia; Eusebio Navarro; María Isabel Navarro-Mendoza; Carlos Pérez-Arques; Victoriano Garre
Journal:  J Fungi (Basel)       Date:  2020-06-26

4.  Comparative host transcriptome in response to pathogenic fungi identifies common and species-specific transcriptional antifungal host response pathways.

Authors:  Mariolina Bruno; Intan M W Dewi; Vicky Matzaraki; Rob Ter Horst; Marina Pekmezovic; Berenice Rösler; Laszlo Groh; Rutger J Röring; Vinod Kumar; Yang Li; Agostinho Carvalho; Mihai G Netea; Jean-Paul Latgé; Mark S Gresnigt; Frank L van de Veerdonk
Journal:  Comput Struct Biotechnol J       Date:  2020-12-26       Impact factor: 7.271

5.  Characteristics of Mucormycosis in Hematological Patients and a Death Prediction Model.

Authors:  Xiaoxu Ma; Ang Li; Weijie Cao; Huiling Li; Suping Zhang; Li Li; Haizhou Xing; Wenliang Tian; Pengfei Jiao; Jiajun Chen; Qingxian Zhang; Aiguo Xu; Lihua Xing
Journal:  Front Microbiol       Date:  2021-12-15       Impact factor: 5.640

Review 6.  Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.

Authors:  Ayushi Sharma; Anjana Goel
Journal:  Folia Microbiol (Praha)       Date:  2022-02-26       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.